Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: J Thorac Oncol. 2015 Jan;10(1):143–147. doi: 10.1097/JTO.0000000000000347

Table 3.

Efficacy Results (N = 75)

Response
 Complete response 6 (8%)
 Partial response 44 (59%)
 Stable disease 20 (27%)
 Progressive disease 5 (7%)
 ORR 67%
Progression-free survival (PFS)
 Median 11 months
 12-month 47%
Overall survival (OS)
 Median 17 months
 12-month 57%
Stage IIIA vs. IIIB
 Median PFS 16 vs. 9 months
 Median OS 19 vs.12 months
PS 0-1 + WL vs. PS 2
 Median PFS 16 vs.10 months
 Median OS 19 vs.13 months